DDInter393 DDInter1376
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Clarithromycin {u} (Compound) resembles {v} (Compound) Troleandomycin
Clarithromycin {u} (Compound) resembles {v} (Compound) Josamycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) ABCB1
Clarithromycin {u} (Compound) upregulates {v} (Gene) SLC25A14
Clarithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Clarithromycin {u} (Compound) downregulates {v} (Gene) TIMM9
Clarithromycin {u} (Compound) causes {v} (Side Effect) Gingival bleeding
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amoxicillin
Clarithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Clarithromycin (Compound) resembles Troleandomycin (Compound)
Clarithromycin (Compound) resembles Josamycin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin
Clarithromycin (Compound) binds ABCB1 (Gene)
Clarithromycin (Compound) upregulates SLC25A14 (Gene)
Clarithromycin (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Clarithromycin (Compound) downregulates TIMM9 (Gene)
Clarithromycin (Compound) causes Gingival bleeding (Side Effect)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Amoxicillin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol